Lipoprotein(a) is associated to atherosclerosis in primary hypercholesterolemia;La lipoproteína(a) se asocia a la presencia de arteriosclerosis en pacientes con hipercolesterolemia primaria

Clinica e Investigacion en Arteriosclerosis

Volumn 26, Issue 4, 2014, Pages 176-183

  Bea, Ana M ^a   Mateo Gallego, Rocío ^a   Jarauta, Estíbaliz ^a   Villa Pobo, Rosa ^a   Calmarza, Pilar ^a   Lamiquiz Moneo, Itziar ^a   Cenarro, Ana ^a   Civeira, Fernando ^a  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

Author keywords

Cardiovascular disease; Carotid intima media thickness; Lipoprotein(a)

Indexed keywords

APOLIPOPROTEIN B; C REACTIVE PROTEIN; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR;

APOB GENE; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; BULB CAROTID ARTERY; CAROTID ARTERY; COMMON CAROTID ARTERY; DISEASE ASSOCIATION; FAMILIAL HYPERCHOLESTEROLEMIA; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HYPERCHOLESTEROLEMIA; LDLR GENE; MAJOR CLINICAL STUDY; RISK FACTOR; SMOKING HABIT; SYSTOLIC BLOOD PRESSURE;

EID: 84904797166     PISSN: 02149168     EISSN: 15781879     Source Type: Journal    
DOI: 10.1016/j.arteri.2014.01.001     Document Type: Article

References (35)

1. Gaubatz J.W., Heideman C., Gotto A.M., Morrisett J.D., Dahlen G.H. Human plasma lipoprotein [a]: Structural properties. J Biol Chem 1983, 258:4582-4589.
2. Boffa M.B., Marcovina S.M., Koschinsky M.L. Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: Mechanistic insights from animal models. Clin Biochem 2004, 37:333-343.
3. Hancock M.A., Boffa M.B., Marcovina S.M., Nesheim M.E., Koschinsky M.L. Inhibition of plasminogen activation by lipoprotein(a): Critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces. J Biol Chem 2003, 278:23260-23269.
4. Tsimikas S., Hall J.L. Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: A rationale for increased efforts to understand its pathophysiology and develop targeted therapies. J Am Coll Cardiol 2012, 60:716-721.
5. Nordestgaard B.G., Chapman M.J., Ray K., Borén J., Andreotti F., Watts G.F., et al. Lipoprotein(a) as a cardiovascular risk factor: Current status. Eur Heart J 2010, 31:2844-2853.
6. Lipoprotein(a) concentration and the risk of coronary heart disease stroke, and nonvascular mortality. JAMA 2009, 302:412-423. The Emerging Risk Factors Collaboration.
7. Catapano A.L., Reiner Z., de Backer G., Graham I., Taskinen M.R., Wiklund O., et al. European Society of Cardiology (ESC); European Atherosclerosis Society (EAS). ESC/EAS Guidelines for the management of dyslipidaemias. The task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011, 217:3-46.
8. Stone N.J., Robinson J., Lichtenstein A.H., Bairey Merz C.N., Lloyd-Jones D.M., Blum C.B., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol 2013, en prensa.
9. Civeira F. International panel on management of familial hypercholesterolemia guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis 2004, 173:55-68.
10. Goldberg A.C., Hopkins P.N., Toth P.P., Ballantyne C.M., Rader D.J., Robinson J.G., et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: Clinical guidance from the National Lipid Association expert panel on familial hypercholesterolemia. J Clin Lipidol 2011, 5(3 Suppl):S1-S8.
11. Masana L., Civeira F., Pedro-Botet J., de Castro I., Pocoví M., Plana N., et al. Expert consensus on the detection and clinical management of familial hypercholesterolemia. Clin Investig Arterioscler 2013, 25:182-193.
12. Nordestgaard B.G., Chapman M.J., Humphries S.E., Ginsberg H.N., Masana L., Descamps O.S., et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: Guidance for clinicians to prevent coronary heart disease: Consensus statement of the European Atherosclerosis Society. Eur Heart J 2013, 34:3478-3490.
13. Orsó E., Ahrens N., Kilalić D., Schmitz G. Familial hypercholesterolemia and lipoprotein(a) hyperlipidemia as independent and combined cardiovascular risk factors. Atheroscler Suppl 2009, 10:74-78.
14. Seed M., Hoppichler F., Reaveley D., McCarthy S., Thompson G.R., Boerwinkle E., et al. Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med 1990, 322:1494-1499.
15. Holmes D.T., Schick B.A., Humphries K.H., Frohlich J. Lipoprotein(a) is an independent risk factor for cardiovascular disease in heterozygous familial hypercholesterolemia. Clin Chem 2005, 51:2067-2073.
16. Nenseter M.S., Lindvig H.W., Ueland T., Langslet G., Ose L., Holven K.B., et al. Lipoprotein(a) levels in coronary heart disease-susceptible and-resistant patients with familial hypercholesterolemia. Atherosclerosis 2011, 216:426-432.
17. Hopkins P.N., Stephenson S., Wu L.L., Riley W.A., Xin Y., Hunt S.C. Evaluation of coronary risk factors in patients with heterozygous familial hypercholesterolemia. Am J Cardiol 2001, 87:547-553.
18. De Sauvage Nolting P.R., Defesche J.C., Buirma R.J., Hutten B.A., Lansberg P.J., Kastelein J.J. Prevalence and significance of cardiovascular risk factors in a large cohort of patients with familial hypercholesterolaemia. J Intern Med 2003, 253:161-168.
19. Alonso R., Mata N., Castillo S., Fuentes F., Saenz P., Muñiz O., et al. Cardiovascular disease in familial hypercholesterolaemia: Influence of low-density lipoprotein receptor mutation type and classic risk factors. Atherosclerosis 2008, 200:315-321.
20. Pitsavos C., Skoumas I., Masoura C., Aznaouridis K., Papadimitriou L., Chrysohoou C., et al. Prevalence and determinants of coronary artery disease in males and females with familial combined hyperlipidaemia. Atherosclerosis 2008, 199:402-407.
21. Jarauta E., Mateo-Gallego R., Gilabert R., Plana N., Junyent M., de Groot E., et al. Carotid atherosclerosis and lipoprotein particle subclasses in familial hypercholesterolaemia and familial combined hyperlipidaemia. Nutr Metab Cardiovasc Dis 2012, 22:591-597.
22. Gómez-Gerique J.A., Gutiérrez-Fuentes J.A., Montoya M.T., Porres A., Rueda A., Avellaneda A., et al. Med Clin (Barc) 1999, 730-735. Lipid profile of the Spanish population: the DRECE (diet and risk of cardiovascular disease in Spain) study. DRECE study group, 113.
23. Dahlen G.H. Potential significance of Lp (a) lipoprote: Clinical and methodological aspects. Genetics of coronary heart disease 1992, 75-88. Institute of Medical Genetics, University of Oslo, Oslo. A.G. Bearn (Ed.).
24. Civeira F., Jarauta E., Cenarro A., García-Otín A.L., Tejedor D., Zambón D., et al. Frequency of low-density lipoprotein receptor gene mutations in patients with a clinical diagnosis of familial combined hyperlipidemia in a clinical setting. J Am Coll Cardiol 2008, 52:1546-1553.
25. Tejedor D., Castillo S., Mozas P., Jiménez E., López M., Tejedor M.T., et al. Reliable low-density DNA array based on allele-specific probes for detection of 118 mutations causing familial hypercholesterolemia. Clin Chem 2005, 51:1137-1144.
26. Meriño-Ibarra E., Puzo J., Jarauta E., Cenarro A., Recalde D., García-Otín A.L., et al. Hyperlipoproteinaemia(a) is a common cause of autosomal dominant hypercholesterolaemia. J Inherit Metab Dis 2007, 30:970-977.
27. Konerman M., Kulkarni K., Toth P.P., Jones S.R. Lipoprotein(a) particle concentration and lipoprotein(a) cholesterol assays yield discordant classification of patients into four physiologically discrete groups. J Clin Lipidol 2012, 6:368-373.
28. Lamon-Fava S., Marcovina S.M., Albers J.J., Kennedy H., Deluca C., White C.C., et al. Lipoprotein(a) levels, apo(a) isoform size, and coronary heart disease risk in the Framingham Offspring Study. J Lipid Res 2011, 52:1181-1187.
29. Talmud P.J., Shah S., Whittall R., Futema M., Howard P., Cooper J.A., et al. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic. Familial hypercholesterolaemia: A case-control study. Lancet 2013, 381:1293-1301.
30. De Castro-Oros I., Pocovi M., Civeira F. The fine line between familial and polygenic hypercholesterolemia. Clin Lipidol 2013, 8:303-306.
31. Konerman M., Kulkarni K., Toth P.P., Jones S.R. Evidence of dependence of lipoprotein(a) on triglyceride and high-density lipoprotein metabolism. J Clin Lipidol 2012, 6:27-32.
32. Clarke R., Peden J.F., Hopewell J.C., Kyriakou T., Goel A., Heath S.C., et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009, 361:2518-2528.
33. Argraves K.M., Kozarsky K.F., Fallon J.T., Harpel P.C., Strickland D.K. The atherogenic lipoprotein Lp(a) is internalized and degraded in a process mediated by the VLDL receptor. J Clin Invest 1997, 100:2170-2181.
34. Berthold H.K., Gouni-Berthold I. Hyperlipoproteinemia(a): Clinical significance and treatment options. Atheroscler Suppl 2013, 14:1-5.
35. Koren M.J., Giugliano R.P., Raal F.J., Sullivan D., Bolognese M., Civeira F., et al. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the open-label study of long-term evaluation against LDL-C (OSLER) randomized trial. Circulation 2014, 129:234-243.